Exelixis, Inc. $EXEL Shares Bought by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp grew its stake in Exelixis, Inc. (NASDAQ:EXEL) by 2.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 438,466 shares of the biotechnology company’s stock after acquiring an additional 12,284 shares during the quarter. Texas Permanent School Fund Corp owned about 0.16% of Exelixis worth $19,325,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Deutsche Bank AG lifted its holdings in Exelixis by 63.8% in the first quarter. Deutsche Bank AG now owns 75,820 shares of the biotechnology company’s stock valued at $2,799,000 after acquiring an additional 29,531 shares during the last quarter. National Bank of Canada FI purchased a new stake in Exelixis in the first quarter valued at approximately $236,000. HighTower Advisors LLC lifted its stake in Exelixis by 7.8% during the first quarter. HighTower Advisors LLC now owns 80,998 shares of the biotechnology company’s stock worth $2,990,000 after purchasing an additional 5,879 shares in the last quarter. Brandywine Global Investment Management LLC purchased a new position in shares of Exelixis during the first quarter worth $5,127,000. Finally, American Century Companies Inc. grew its stake in shares of Exelixis by 44.9% in the first quarter. American Century Companies Inc. now owns 602,615 shares of the biotechnology company’s stock valued at $22,249,000 after buying an additional 186,750 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of research reports. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Sunday. TD Cowen upped their price target on Exelixis from $44.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 26th. HC Wainwright boosted their price objective on Exelixis from $46.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Guggenheim cut shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.45.

Exelixis Trading Down 1.2%

Shares of Exelixis stock opened at $40.88 on Monday. The company has a fifty day simple moving average of $40.77 and a 200-day simple moving average of $40.80. The stock has a market cap of $10.96 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 0.74 and a beta of 0.40. Exelixis, Inc. has a 12-month low of $31.90 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.68 by $0.10. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The firm had revenue of $597.76 million for the quarter, compared to analyst estimates of $590.04 million. During the same period last year, the business earned $0.47 EPS. Exelixis’s revenue for the quarter was up 10.8% compared to the same quarter last year. On average, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In related news, EVP Patrick J. Haley sold 28,043 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $42.58, for a total value of $1,194,070.94. Following the completion of the sale, the executive vice president directly owned 374,029 shares of the company’s stock, valued at $15,926,154.82. This represents a 6.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stelios Papadopoulos sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the completion of the sale, the director owned 1,189,228 shares of the company’s stock, valued at approximately $51,790,879.40. This represents a 7.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 245,235 shares of company stock valued at $10,490,600 over the last quarter. Company insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.